Frank Barry

Frank Barry


Frank Barry is Professor of Cellular Therapy at the Regenerative Medicine Institute (REMEDI), National University of Ireland Galway. His research focuses on the development of new repair strategies in stem cell therapy and gene therapy in orthopaedics.

In a career that has spanned both industry and academia, he has been a driver in the development of cellular therapy as a biological repair strategy. Professor Barry is a co-founder of the centre of excellence in stem cell technology at NUI Galway at the Regenerative Medicine Institute (REMEDI). Additionally, he established advanced manufacturing capacity in preparation of bone marrow-derived stem cells in the Centre for Cell Manufacturing Ireland, leading to fully GMP-compliant manufacturing licence. He also developed a research programme in stem cell therapy leading to FDA approval for the first allogeneic stem cell therapy in arthritic disease. His spin-out company, Orbsen Therapeutics, specialises in proprietary stem cell selection technology.

He has contributed to the fields of tissue engineering and regenerative medicine by developing innovative and successful cellular therapies for the treatment of acute joint injury and arthritic disease.  This has included the generation of a large body of new data in ground-breaking preclinical studies, and has lead to the first phase of clinical testing of mesenchymal stem cells in clinical trials for joint injury.

Professor Barry received the prestigious Marshall Urist Award for excellence in research in tissue regeneration by the Orthopaeadic Research Society – the first scientist outside the USA to receive this honour. In 2013 he was inducted as a Fellow of the International Cartilage Repair Society.

Professor Barry has authored over 125 papers and been awarded seven patents.

Professor Barry coordinates an EU Consortium and sits on the Advisory Boards of the MIT Centre for Biomedical Engineering and the International Cartilage Repair Society. He is also a member of the NIH SBIR Study Section for Orthopaedic Tissue Engineering and the Corporate Relations Committee of the Association of Biomolecular Resource Facilities.

Related Links